Manson Fok - Aug 3, 2022 Form 4 Insider Report for Athenex, Inc. (ATNXQ)

Role
Director
Signature
/s/ Staci Holquist, Attorney-in-Fact
Stock symbol
ATNXQ
Transactions as of
Aug 3, 2022
Transactions value $
$0
Form type
4
Date filed
8/30/2022, 06:30 PM
Previous filing
Jul 21, 2022
Next filing
Oct 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATNXQ Common Stock Options Exercise +6.25K +0.31% 2.03M Aug 3, 2022 Direct F1
holding ATNXQ Common Stock 679K Aug 3, 2022 By Avalon Biomedical (Management) Limited F2, F3
holding ATNXQ Common Stock 107K Aug 3, 2022 By Avalon Polytom (HK) Limited F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATNXQ Restricted Stock Units Options Exercise $0 -6.25K -100% $0.00* 0 Aug 3, 2022 Common Stock 6.25K Direct F1
holding ATNXQ Stock Option (Right to Buy) 80K Aug 3, 2022 Common Stock 80K $4.55 Direct
holding ATNXQ Stock Option (Right to Buy) 48K Aug 3, 2022 Common Stock 48K $4.55 Direct
holding ATNXQ Stock Option (Right to Buy) 20K Aug 3, 2022 Common Stock 20K $4.55 Direct
holding ATNXQ Stock Option (Right to Buy) 40K Aug 3, 2022 Common Stock 40K $4.55 Direct
holding ATNXQ Stock Option (Right to Buy) 48K Aug 3, 2022 Common Stock 48K $7.50 Direct
holding ATNXQ Stock Option (Right to Buy) 48K Aug 3, 2022 Common Stock 48K $9.00 Direct
holding ATNXQ Stock Option (Right to Buy) 27K Aug 3, 2022 Common Stock 27K $11.00 Direct
holding ATNXQ Stock Option (Right to Buy) 54.9K Aug 3, 2022 Common Stock 54.9K $9.00 By Avalon Biomedical (Management) Limited F2, F3
holding ATNXQ Stock Option (Right to Buy) 15K Aug 3, 2022 Common Stock 15K $17.30 Direct
holding ATNXQ Stock Option (Right to Buy) 10K Aug 3, 2022 Common Stock 10K $13.17 Direct F5
holding ATNXQ Stock Option (Right to Buy) 10K Aug 3, 2022 Common Stock 10K $12.45 Direct F6
holding ATNXQ Stock Option (Right to Buy) 6.25K Aug 3, 2022 Common Stock 6.25K $3.80 Direct
holding ATNXQ Stock Option (Right to Buy) 12.5K Aug 3, 2022 Common Stock 12.5K $0.46 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units, which convert into common stock on a one-for one basis, vested on August 3, 2022.
F2 Avalon Biomedical (Management) Limited ("Avalon Biomedical") is an indirect wholly-owned subsidiary of Avalon Global Holdings Limited ("Avalon Global"). Mason Fok, M.B., B.S. ("Dr. Fok"), together with his spouse, own all of the outstanding interests in Sino Glory Developments Limited, which owns 34.63% of the outstanding interests in Avalon Global, and Dr. Fok serves on the board of directors of Avalon Global and has shared voting and dispositive power with respect to the shares held by Avalon Biomedical.
F3 Dr. Fok disclaims beneficial ownership of the reported securities except to the extent, if any, of its or his pecuniary interest therein, and this report shall not be deemed an admission that Dr. Fok is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F4 These shares were acquired pursuant to the terms of a License Agreement dated as of June 29, 2018 by and between Athenex Therapeutics Limited, a wholly-owned subsidiary of Athenex, Inc. ("Athenex") and Avalon Polytom (HK) Limited, a majority-owned affiliate of Avalon Global. The number of shares was determined by dividing $2.0 million by the closing price of Athenex common stock on June 29, 2018.
F5 This option vests in four equal annual installments beginning on February 28, 2020.
F6 This option vests in four equal annual installments beginning on June 5, 2021.
F7 This option vests on June 28, 2023.